RealFeedApp Phase 3 study 304 evaluates VDPHL01 in 536 men
The company will hold a conference call on October 19, 2026, to review Part A topline results from the randomized, double-blind, placebo-controlled Phase 3 study 304 involving 536 men with mild-to-moderate pattern hair loss.
- Field
- ageing and longevity
- What they did
- Veradermics will present Phase 3 trial results for study 304, which tested a new extended-release oral minoxidil formulation (VDPHL01) in 536 men with hair loss.
- Why it matters
- The study aims to demonstrate that the new drug formulation provides sustained hair growth without the high peak concentrations found in standard oral minoxidil.
#veradermics#hair loss#phase 3#clinical trial#minoxidil
